ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CRA Family Trust & PACs ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the registered shareholder(s) in English language newspaper - Business Standard on 3rd November, 2020. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations, 2015')
Pursuant to Regulation 23(9) of the Listing Regulations, 2015, we enclose herewith Disclosure of Related Party Transactions, on a consolidated basis, for the period ended 30th September, 2020. We request you to kindly take the same on record.
Buy Alembic Pharmaceuticals; target of Rs 1286 KR Choksey
KR Choksey is bullish on Alembic Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1286 in its research report dated October 26, 2020.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate have requested the Company for issue of duplicate share certificate. Alembic Pharma gets USFDA nod for elevated intraocular pressure drug
Drug firm Alembic Pharmaceuticals on Monday said it has received final nod from the US health regulator for its Timolol Maleate ophthalmic gel-formi ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Buy Alembic Pharma; target of Rs 1180: YES Securities
YES Securities is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 1180 in its research report dated October 22, 2020.
Earnings Call Transcript - Q2FY21 for Alembic Pharmaceuticals
Conference Call with Alembic Pharmaceuticals Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.